| 1 | Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis | 62.3 | 846 | Citations (PDF) |
| 2 | Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis | 62.3 | 278 | Citations (PDF) |
| 3 | Different effects of antihypertensive treatment on office and ambulatory blood pressure | 2.2 | 16 | Citations (PDF) |
| 4 | Estimation of metabolic syndrome heritability in three large populations including full pedigree and genomic information | 2.9 | 5 | Citations (PDF) |
| 5 | Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome | 2.2 | 42 | Citations (PDF) |
| 6 | Isolated systolic hypertension in the young | 2.2 | 77 | Citations (PDF) |
| 7 | Best antihypertensive strategies to improve blood pressure control in Latin America | 2.2 | 13 | Citations (PDF) |
| 8 | Osmotic indices and kidney concentrating activity: population-based data on correlates and prognostic power | 0.8 | 7 | Citations (PDF) |
| 9 | MASked-unconTrolled hypERtension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol | 1.9 | 37 | Citations (PDF) |
| 10 | 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension | 2.2 | 807 | Citations (PDF) |
| 11 | 2018 Practice guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension | 1.7 | 711 | Citations (PDF) |
| 12 | 2018 ESC/ESH Guidelines for the management of arterial hypertension | 2.2 | 2,533 | Citations (PDF) |
| 13 | 2018 ESC/ESH Guidelines for the management of arterial hypertension | 2.2 | 8,608 | Citations (PDF) |
| 14 | Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality | 2.2 | 84 | Citations (PDF) |
| 15 | Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data | 8.1 | 102 | Citations (PDF) |
| 16 | Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality | 2.2 | 102 | Citations (PDF) |
| 17 | Clinical Perspective on Antihypertensive Drug Treatment in Adults With Grade 1 Hypertension and Low-to-Moderate Cardiovascular Risk: An International Expert Consultation | 3.0 | 19 | Citations (PDF) |
| 18 | Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5 | 10.5 | 202 | Citations (PDF) |
| 19 | Guidelines, position studies, and blood vessel research | 2.2 | 0 | Citations (PDF) |
| 20 | Proteomic-Biostatistic Integrated Approach for Finding the Underlying Molecular Determinants of Hypertension in Human Plasma | 6.6 | 25 | Citations (PDF) |
| 21 | Prognostic, diagnostic, and therapeutic advances in hypertension | 2.2 | 0 | Citations (PDF) |
| 22 | From risk factors to treatment of hypertension | 2.2 | 5 | Citations (PDF) |
| 23 | 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents | 2.2 | 1,163 | Citations (PDF) |
| 24 | Prediction, diagnosis and treatment of hypertension | 2.2 | 0 | Citations (PDF) |
| 25 | From pregnancy to childhood and adulthood | 2.2 | 0 | Citations (PDF) |
| 26 | Challenges of antihypertensive treatment | 2.2 | 0 | Citations (PDF) |
| 27 | Hypertension Guidelines: Is It Time to Reappraise Blood Pressure Thresholds and Targets? | 6.6 | 20 | Citations (PDF) |
| 28 | Methodology and technology for peripheral and central blood pressure and blood pressure variability measurement | 2.2 | 135 | Citations (PDF) |
| 29 | Prediction and prevention of hypertension-related events | 2.2 | 0 | Citations (PDF) |
| 30 | Management of the hypertensive patient with elevated heart rate | 2.2 | 89 | Citations (PDF) |
| 31 | Dietary, clinical and therapeutic aspects of hypertension | 2.2 | 0 | Citations (PDF) |
| 32 | Obesity, diabetes, and antidiabetic treatment | 2.2 | 3 | Citations (PDF) |
| 33 | Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial | 2.2 | 103 | Citations (PDF) |
| 34 | No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial | 1.7 | 63 | Citations (PDF) |
| 35 | From inflammation to renal denervation in hypertension research | 2.2 | 0 | Citations (PDF) |
| 36 | Studying arterial wall in hypertension | 2.2 | 0 | Citations (PDF) |
| 37 | From dietary factors to drug adherence | 2.2 | 1 | Citations (PDF) |
| 38 | Factors influencing blood pressure levels | 2.2 | 6 | Citations (PDF) |
| 39 | Large and small vessel disease and other aspects of hypertension | 2.2 | 1 | Citations (PDF) |
| 40 | Lifestyle and therapeutic interventions for hypertension | 2.2 | 1 | Citations (PDF) |
| 41 | Dietary and metabolic aspects of hypertension and hypertension-related organ damage | 2.2 | 0 | Citations (PDF) |
| 42 | Hypertension-related mortality and morbidity | 2.2 | 5 | Citations (PDF) |
| 43 | From the pathophysiological to the epidemiological approach to hypertension research | 2.2 | 0 | Citations (PDF) |
| 44 | Population-based dose–response curve of glomerular filtration rate to dietary protein intake | 0.8 | 19 | Citations (PDF) |
| 45 | From blood pressure measurement to antihypertensive treatment | 2.2 | 0 | Citations (PDF) |
| 46 | Antihypertensive treatment is not a risk factor for major cardiovascular events in the Gubbio residential cohort study | 2.2 | 16 | Citations (PDF) |
| 47 | New evidence and critical reappraisal of available evidence | 2.2 | 11 | Citations (PDF) |
| 48 | Obesity and other aspects of hypertension | 2.2 | 2 | Citations (PDF) |
| 49 | Effects of blood pressure lowering on outcome incidence in hypertension | 2.2 | 262 | Citations (PDF) |
| 50 | Role of socio-economic factors, blood pressure measurement, and therapeutic strategies in hypertension | 2.2 | 1 | Citations (PDF) |
| 51 | Randomized Controlled Trials of Blood Pressure Lowering in Hypertension | 13.2 | 149 | Citations (PDF) |
| 52 | Protein intake and kidney function in the middle-age population: contrast between cross-sectional and longitudinal data | 0.8 | 71 | Citations (PDF) |
| 53 | Cohort Profile: The Gubbio Population Study | 4.9 | 25 | Citations (PDF) |
| 54 | Influence of high cardiovascular risk in asymptomatic people on the duration and cost of sick leave: results of the ICARIA study | 2.2 | 25 | Citations (PDF) |
| 55 | 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension | 1.7 | 597 | Citations (PDF) |
| 56 | Estimating the glomerular filtration rate in the Spanish working population | 2.2 | 6 | Citations (PDF) |
| 57 | Challenges in hypertension | 2.2 | 7 | Citations (PDF) |
| 58 | Investigating multiple aspects of blood pressure control | 2.2 | 0 | Citations (PDF) |
| 59 | European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring | 2.2 | 851 | Citations (PDF) |
| 60 | What format for hypertension guidelines | 2.2 | 13 | Citations (PDF) |
| 61 | Predictive medicine, pathophysiology and therapeutics | 2.2 | 0 | Citations (PDF) |
| 62 | A look at differences | 2.2 | 0 | Citations (PDF) |
| 63 | Recommendations for practice and mechanistic investigations | 2.2 | 0 | Citations (PDF) |
| 64 | Hypertension-related organ damage and cardiovascular risk | 2.2 | 0 | Citations (PDF) |
| 65 | Salt, inflammation, pathophysiological mechanisms, and organ damage in hypertension | 2.2 | 1 | Citations (PDF) |
| 66 | Focus on clinical problems | 2.2 | 0 | Citations (PDF) |
| 67 | Predictive, mechanistic, and therapeutic studies on hypertension and cardiovascular morbidity and mortality | 2.2 | 1 | Citations (PDF) |
| 68 | From pathophysiology to therapeutic interventions | 2.2 | 1 | Citations (PDF) |
| 69 | Challenges of hypertension and hypertension treatment | 2.2 | 1 | Citations (PDF) |
| 70 | Heritability of blood pressure through latent curve trajectories in families from the Gubbio population study | 2.2 | 7 | Citations (PDF) |
| 71 | Relationships of different types of event to cardiovascular death in trials of antihypertensive treatment | 2.2 | 13 | Citations (PDF) |
| 72 | Target blood pressure in elderly hypertensive patients and in patients with diabetes mellitus | 2.2 | 13 | Citations (PDF) |
| 73 | Effect of Long-Term Antihypertensive Treatment on White-Coat Hypertension | 6.6 | 54 | Citations (PDF) |
| 74 | Association of systolic blood pressure levels with cardiovascular events and all-cause mortality among older adults taking antihypertensive medication | 2.2 | 63 | Citations (PDF) |
| 75 | Typical and atypical coronary heart disease deaths and their different relationships with risk factors. The Gubbio residential cohort Study | 2.2 | 16 | Citations (PDF) |
| 76 | Serum uric acid and eGFR_CKDEPI differently predict long-term cardiovascular events and all causes of deaths in a residential cohort | 2.2 | 38 | Citations (PDF) |
| 77 | Consenso latinoamericano de hipertensión en pacientes con diabetes tipo 2 y síndrome metabólico | 0.4 | 9 | Citations (PDF) |
| 78 | Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient | 2.2 | 65 | Citations (PDF) |
| 79 | Consenso latino-americano de hipertensão em pacientes com diabetes tipo 2 e síndrome metabólica | 1.4 | 23 | Citations (PDF) |
| 80 | Guía de práctica clínica de la ESH/ESC para el manejo de la hipertensión arterial (2013) | 0.9 | 10 | Citations (PDF) |
| 81 | Guía de práctica clínica de la ESH/ESC para el manejo de la hipertensión arterial (2013) | 1.1 | 27 | Citations (PDF) |
| 82 | 2013 ESH/ESC Guidelines for the management of arterial hypertension | 1.7 | 367 | Citations (PDF) |
| 83 | 2013 ESH/ESC Guidelines for the management of arterial hypertension | 2.2 | 5,474 | Citations (PDF) |
| 84 | What to look for in the current issue? | 2.2 | 1 | Citations (PDF) |
| 85 | Contributions to debated problems | 2.2 | 1 | Citations (PDF) |
| 86 | An outlook on the content of this journal issue | 2.2 | 0 | Citations (PDF) |
| 87 | Editor's corner | 2.2 | 6 | Citations (PDF) |
| 88 | Facets of hypertension research | 2.2 | 0 | Citations (PDF) |
| 89 | Investigation clues for prognosis, diagnosis and therapeutic strategies | 2.2 | 0 | Citations (PDF) |
| 90 | Differences between office and ambulatory blood pressures in children and adolescents attending a hospital hypertension clinic | 2.2 | 26 | Citations (PDF) |
| 91 | Ambulatory blood pressure monitoring, arterial function and other problems concerning hypertension | 2.2 | 0 | Citations (PDF) |
| 92 | Vascular and parenchymal lesions along with enhanced neurogenesis characterize the brain of asymptomatic stroke-prone spontaneous hypertensive rats | 2.2 | 5 | Citations (PDF) |
| 93 | European Society of Hypertension Position Paper on Ambulatory Blood Pressure Monitoring | 2.2 | 1,231 | Citations (PDF) |
| 94 | Guidelines, organ damage, diagnostic procedures and treatment | 2.2 | 0 | Citations (PDF) |
| 95 | 2013 ESH/ESC Guidelines for the management of arterial hypertension | 2.2 | 4,327 | Citations (PDF) |
| 96 | What really matters is not what the authors meant to say, it is how their work is read | 2.2 | 0 | Citations (PDF) |
| 97 | 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) | 2.2 | 836 | Citations (PDF) |
| 98 | Contributions to management of hypertension from papers in the current issue | 2.2 | 0 | Citations (PDF) |
| 99 | Latin American consensus on hypertension in patients with diabetes type 2 and metabolic syndrome | 2.2 | 65 | Citations (PDF) |
| 100 | Editor's Corner | 2.2 | 0 | Citations (PDF) |
| 101 | Guidelines and research upon which guidelines are founded | 2.2 | 0 | Citations (PDF) |
| 102 | Renal Effects of Felodipine in Hypertension | 11.4 | 7 | Citations (PDF) |
| 103 | Natriuretic Effects of Calcium Antagonists | 11.4 | 1 | Citations (PDF) |
| 104 | First-Line Treatment in Hypertension | 11.4 | 1 | Citations (PDF) |
| 105 | Preliminary Clinical Experience with Calcium Antagonists in Atherosclerosis | 11.4 | 2 | Citations (PDF) |
| 106 | The 24-Hour Efficacy of a New Once-Daily Formulation of Nifedipine | 11.4 | 3 | Citations (PDF) |
| 107 | Safety Profile of Lacidipine | 11.4 | 4 | Citations (PDF) |
| 108 | Closing Remarks: Current Position of Calcium Channel Antagonists in Hypertension ??? the Role of Manidipine | 11.4 | 1 | Citations (PDF) |
| 109 | Zofenopril plus HydrochlorothiazideDrugs, 2012, 66, 1107-1115 | 11.4 | 11 | Citations (PDF) |
| 110 | Visit-to-Visit Blood Pressure Variability, Carotid Atherosclerosis, and Cardiovascular Events in the European Lacidipine Study on Atherosclerosis | 18.1 | 143 | Citations (PDF) |
| 111 | Cardiovascular outcomes in hypertensive patients | 2.2 | 25 | Citations (PDF) |
| 112 | Twenty-four hour and early morning blood pressure control of olmesartan vs. ramipril in elderly hypertensive patients | 2.2 | 18 | Citations (PDF) |
| 113 | Visit-to-visit blood pressure variability in the European Lacidipine Study on Atherosclerosis | 2.2 | 85 | Citations (PDF) |
| 114 | Higher cardiovascular risk and impaired benefit of antihypertensive treatment in hypertensive patients requiring additional drugs on top of randomized therapy | 2.2 | 14 | Citations (PDF) |
| 115 | Association of central and peripheral pulse pressure with intermediate cardiovascular phenotypes | 2.2 | 37 | Citations (PDF) |
| 116 | Information, discernment and learning | 2.2 | 5 | Citations (PDF) |
| 117 | Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials | 62.3 | 781 | Citations (PDF) |
| 118 | Usefulness of Heart Rate to Predict Cardiac Events in Treated Patients With High-Risk Systemic Hypertension | 1.8 | 167 | Citations (PDF) |
| 119 | The role of HDL cholesterol in metabolic syndrome predicting cardiovascular events. The Gubbio population study | 3.2 | 24 | Citations (PDF) |
| 120 | Evidence and wisdom: recommendations for forthcoming guidelines | 2.2 | 10 | Citations (PDF) |
| 121 | Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial | 2.2 | 121 | Citations (PDF) |
| 122 | Effects of individual risk factors on the residual risk of cardiovascular events in a population of treated Chinese patients with hypertension: data from the Felodipine Event Reduction (FEVER) study | 2.2 | 16 | Citations (PDF) |
| 123 | Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study | 2.2 | 43 | Citations (PDF) |
| 124 | Guías Latinoamericanas de Hipertensión Arterial | 0.1 | 12 | Citations (PDF) |
| 125 | Genome-Wide Association Study of Blood Pressure Extremes Identifies Variant near UMOD Associated with Hypertension | 3.2 | 333 | Citations (PDF) |
| 126 | Blood pressure targets of antihypertensive treatment: up and down the J-shaped curve | 2.2 | 65 | Citations (PDF) |
| 127 | Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial | 0.1 | 50 | Citations (PDF) |
| 128 | Aspirin Is Beneficial in Hypertensive Patients With Chronic Kidney Disease | 2.3 | 182 | Citations (PDF) |
| 129 | Baseline Values but Not Treatment-Induced Changes in Carotid Intima-Media Thickness Predict Incident Cardiovascular Events in Treated Hypertensive Patients | 18.1 | 127 | Citations (PDF) |
| 130 | Indexation of left ventricular mass to body surface area and height to allometric power of 2.7: is the difference limited to obese hypertensives? | 2.6 | 87 | Citations (PDF) |
| 131 | Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document | 2.2 | 1,493 | Citations (PDF) |
| 132 | Left and right ventricular structural changes in obese hypertensives | 1.7 | 19 | Citations (PDF) |
| 133 | Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document | 1.7 | 357 | Citations (PDF) |
| 134 | Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials | 62.3 | 3,379 | Citations (PDF) |
| 135 | Effects of antihypertensive treatment on ultrasound measures of myocardial fibrosis in hypertensive patients with left ventricular hypertrophy: results of a randomized trial comparing the angiotensin receptor antagonist, candesartan and the angiotensin-converting enzyme inhibitor, enalapril | 2.2 | 14 | Citations (PDF) |
| 136 | Is retinal arteriolar–venular ratio associated with cardiac and extracardiac organ damage in essential hypertension? | 2.2 | 37 | Citations (PDF) |
| 137 | Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced? | 2.2 | 96 | Citations (PDF) |
| 138 | Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension | 2.2 | 639 | Citations (PDF) |
| 139 | Prevalence and clinical correlates of right ventricular hypertrophy in essential hypertension | 2.2 | 36 | Citations (PDF) |
| 140 | Improving cardiovascular risk stratification in essential hypertensive patients by indexing left ventricular mass to height2.7 | 2.2 | 33 | Citations (PDF) |
| 141 | Twenty-year cardiovascular and all-cause mortality trends and changes in cardiovascular risk factors in Gubbio, Italy: the role of blood pressure changes | 2.2 | 19 | Citations (PDF) |
| 142 | The dilemma of placebo controlled studies: scientific evidence, guidelines, ethics and regulatory recommendations | 2.2 | 5 | Citations (PDF) |
| 143 | Management of hypertension in patients with left ventricular hypertrophy | 4.8 | 8 | Citations (PDF) |
| 144 | Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: The VALUE trial | 1.7 | 12 | Citations (PDF) |
| 145 | The 24 h blood pressure-R–R interval relation in ambulatory monitoring | 3.0 | 4 | Citations (PDF) |
| 146 | Studies on Left Ventricular Hypertrophy Regression in Arterial Hypertension: A Clear Message for the Clinician? | 2.0 | 28 | Citations (PDF) |
| 147 | Editing a scientific journal: problems and challenges | 2.2 | 7 | Citations (PDF) |
| 148 | European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring | 2.2 | 737 | Citations (PDF) |
| 149 | Metabolic syndrome and target organ damage: role of blood pressure | 1.8 | 17 | Citations (PDF) |
| 150 | Metabolic syndrome and multiple organ damage in essential hypertension | 1.7 | 17 | Citations (PDF) |
| 151 | Definition of Kidney Dysfunction as a Cardiovascular Risk FactorUse of Urinary Albumin Excretion and Estimated Glomerular Filtration Rate | 8.1 | 89 | Citations (PDF) |
| 152 | The Hyper‐Pract Study: A multicentre survey on the accuracy of the echocardiographic assessment of hypertensive left ventricular hypertrophy in clinical practice | 1.7 | 13 | Citations (PDF) |
| 153 | Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results | 2.2 | 68 | Citations (PDF) |
| 154 | Reading and citing from the Journal of Hypertension | 2.2 | 1 | Citations (PDF) |
| 155 | Choice of antihypertensive drugs in the European Society of Hypertension–European Society of Cardiology guidelines: specific indications rather than ranking for general usage | 2.2 | 31 | Citations (PDF) |
| 156 | Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial | 2.2 | 202 | Citations (PDF) |
| 157 | Prevalence of type 2 diabetes among patients with hypertension under the care of 30 Italian clinics of hypertension: results of the (Iper)tensione and (dia)bete study | 2.2 | 28 | Citations (PDF) |
| 158 | Prevalence and correlates of multiple organ damage in a never-treated hypertensive population: role of ambulatory blood pressure | 0.7 | 21 | Citations (PDF) |
| 159 | Body mass index, nocturnal fall in blood pressure and organ damage in untreated essential hypertensive patients | 0.7 | 29 | Citations (PDF) |
| 160 | Angiotensin II receptor blockers and cardiovascular protection: Focus on left ventricular hypertrophy regression and atrial fibrillation prevention | 4.1 | 11 | Citations (PDF) |
| 161 | Angiotensin II receptor blockers and cardiovascular protection: Focus on left ventricular hypertrophy regression and atrial fibrillation prevention | 4.1 | 22 | Citations (PDF) |
| 162 | 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) | 2.2 | 1,641 | Citations (PDF) |
| 163 | Ambulatory blood pressure, target organ damage and aortic root size in never-treated essential hypertensive patients | 2.6 | 39 | Citations (PDF) |
| 164 | Where is hypertension research going? | 2.2 | 2 | Citations (PDF) |
| 165 | 2007 Guidelines for the Management of Arterial Hypertension | 2.2 | 4,881 | Citations (PDF) |
| 166 | Metabolic Syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) Study | 6.6 | 229 | Citations (PDF) |
| 167 | Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial | 2.2 | 71 | Citations (PDF) |
| 168 | 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension | 2.2 | 1,166 | Citations (PDF) |
| 169 | Assessment of long-term antihypertensive treatment by clinic and ambulatory blood pressure: data from the European Lacidipine Study on Atherosclerosis | 2.2 | 60 | Citations (PDF) |
| 170 | Reading and citing from the Journal of Hypertension | 2.2 | 1 | Citations (PDF) |
| 171 | Reproducibility of dipping/nondipping pattern in untreated essential hypertensive patients: impact of sex and age | 0.7 | 39 | Citations (PDF) |
| 172 | How reliable is isolated clinical hypertension defined by a single 24-h ambulatory blood pressure monitoring? | 2.2 | 20 | Citations (PDF) |
| 173 | Left ventricular diastolic dysfunction in elderly hypertensives: results of the APROS-diadys study | 2.2 | 63 | Citations (PDF) |
| 174 | Blood pressure control in Italy: results of recent surveys on hypertension | 2.2 | 119 | Citations (PDF) |
| 175 | Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima–media thickness | 2.2 | 73 | Citations (PDF) |
| 176 | Age and Target Organ Damage in Essential Hypertension: Role of the Metabolic Syndrome | 2.0 | 54 | Citations (PDF) |
| 177 | Lack of Association Between Serum Uric Acid and Organ Damage in a Never-Treated Essential Hypertensive Population at Low Prevalence of Hyperuricemia | 2.0 | 52 | Citations (PDF) |
| 178 | 2007 ESH‐ESC Guidelines for the management of arterial hypertension | 1.7 | 312 | Citations (PDF) |
| 179 | Guías de práctica clínica para el tratamiento de la hipertensión arterial 2007 | 1.1 | 53 | Citations (PDF) |
| 180 | Effects of angiotensin II receptor blockade‐based therapy with losartan on left ventricular hypertrophy and geometry in previously treated hypertensive patients | 1.7 | 7 | Citations (PDF) |
| 181 | Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial | 2.2 | 139 | Citations (PDF) |
| 182 | Prevalence and correlates of aortic root dilatation in patients with essential hypertension: relationship with cardiac and extracardiac target organ damage | 2.2 | 87 | Citations (PDF) |
| 183 | Hypertensive myocardial fibrosis | 0.8 | 82 | Citations (PDF) |
| 184 | Short-term reproducibility of a non-dipping pattern in type 2 diabetic hypertensive patients | 2.2 | 74 | Citations (PDF) |
| 185 | Hypertension: which aspects of hypertension should we impact on and how? | 2.2 | 12 | Citations (PDF) |
| 186 | Left ventricular hypertrophy and cardiovascular risk stratification: impact and cost-effectiveness of echocardiography in recently diagnosed essential hypertensives | 2.2 | 54 | Citations (PDF) |
| 187 | Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting | 2.2 | 181 | Citations (PDF) |
| 188 | Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial | 2.2 | 154 | Citations (PDF) |
| 189 | Low glomerular filtration in the population: Prevalence, associated disorders, and awareness | 5.3 | 131 | Citations (PDF) |
| 190 | Reading and citing from the Journal of Hypertension: an article listed as the top cited medical paper in 2003–2005 | 2.2 | 1 | Citations (PDF) |
| 191 | On the state of the Journal | 2.2 | 0 | Citations (PDF) |
| 192 | Carotid atherosclerosis and cardiovascular risk stratification: Role and cost‐effectiveness of echo‐Doppler examination in untreated essential hypertensives | 1.7 | 4 | Citations (PDF) |
| 193 | The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial | 6.6 | 146 | Citations (PDF) |
| 194 | Targeting hypertension with valsartan: Lessons learned from the Valsartan/HCTZ versus Amlodipine in stage II hypertensive patients (VASt) trial. | 6.1 | 5 | Citations (PDF) |
| 195 | Low Muscular Mass and Overestimation of Microalbuminuria by Urinary Albumin/Creatinine Ratio | 6.6 | 56 | Citations (PDF) |
| 196 | Nocturnal non‐dipping pattern in untreated hypertensives at different cardiovascular risk according to the 2003 ESH/ESC guidelines | 1.7 | 17 | Citations (PDF) |
| 197 | Findings and implications of the Study on COgnition and Prognosis in the Elderly (SCOPE) – A review | 1.7 | 50 | Citations (PDF) |
| 198 | Results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial by geographical region | 2.2 | 26 | Citations (PDF) |
| 199 | The José L. Rodicio Festschrift | 2.2 | 0 | Citations (PDF) |
| 200 | Ambulatory blood pressure, target organ damage and left atrial size in never-treated essential hypertensive individuals | 2.2 | 26 | Citations (PDF) |
| 201 | Carotid wall composition in hypertensive patients after 4-year treatment with lacidipine or atenolol: an echoreflectivity study | 2.2 | 16 | Citations (PDF) |
| 202 | The Journal of Hypertension: web visits and citations | 2.2 | 1 | Citations (PDF) |
| 203 | Quality control of B-mode ultrasonic measurement of carotid artery intima–media thickness: the European Lacidipine Study on Atherosclerosis | 2.2 | 28 | Citations (PDF) |
| 204 | The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients | 2.2 | 336 | Citations (PDF) |
| 205 | Different relation between 24-h blood pressure and distensibility at different peripheral arteries. Data from the European Lacidipine Study on Atherosclerosis (ELSA) | 2.2 | 13 | Citations (PDF) |
| 206 | Cardiac structural and functional changes during long-term antihypertensive treatment with lacidipine and atenolol in the European Lacidipine Study on Atherosclerosis (ELSA) | 2.2 | 28 | Citations (PDF) |
| 207 | Menopause-related blood pressure increase and its relationship to age and body mass index: the SIMONA epidemiological study | 2.2 | 138 | Citations (PDF) |
| 208 | Metabolic syndrome score and ambulatory blood pressure in untreated essential hypertension | 0.7 | 16 | Citations (PDF) |
| 209 | Prevalence and correlates of left atrial enlargement in essential hypertension: role of ventricular geometry and the metabolic syndrome | 2.2 | 103 | Citations (PDF) |
| 210 | One hundred years of auscultatory blood pressure | 2.2 | 13 | Citations (PDF) |
| 211 | The Study on COgnition and Prognosis in the Elderly (SCOPE) – Major CV events and stroke in subgroups of patients | 1.7 | 77 | Citations (PDF) |
| 212 | Prevalence of home blood pressure measurement among selected hypertensive patients: Results of a multicenter survey from six hospital outpatient hypertension clinics in Italy | 1.7 | 56 | Citations (PDF) |
| 213 | Riskard 2005. New tools for prediction of cardiovascular disease risk derived from Italian population studies | 3.2 | 49 | Citations (PDF) |
| 214 | Effect of Baseline Cognitive Function and Antihypertensive Treatment on Cognitive and Cardiovascular Outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE) | 2.0 | 166 | Citations (PDF) |
| 215 | Indexation Criteria of Ventricular Mass and Predictive Role of Blood Pressure and Body Composition | 2.0 | 36 | Citations (PDF) |
| 216 | Cardiovascular risk stratification according to the 2003 ESH‐ESC guidelines in uncomplicated patients with essential hypertension: comparison with the 1999 WHO/ISH guidelines criteria | 1.7 | 22 | Citations (PDF) |
| 217 | Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide‐mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients | 1.7 | 69 | Citations (PDF) |
| 218 | Different Effects of Antihypertensive Therapies Based on Losartan or Atenolol on Ultrasound and Biochemical Markers of Myocardial Fibrosis | 18.1 | 159 | Citations (PDF) |
| 219 | Looking back, looking forward | 2.2 | 25 | Citations (PDF) |
| 220 | Relation of urinary albumin excretion to coronary heart disease and low renal function: Role of blood pressure | 5.3 | 26 | Citations (PDF) |
| 221 | Left ventricular and carotid structure in untreated, uncomplicated essential hypertension: results from the Assessment Prognostic Risk Observational Survey (APROS) | 2.6 | 58 | Citations (PDF) |
| 222 | Is the nocturnal fall in blood pressure reduced in essential hypertensive patients with metabolic syndrome? | 1.7 | 16 | Citations (PDF) |
| 223 | Different Effects of Antihypertensive Regimens Based on Fosinopril or Hydrochlorothiazide With or Without Lipid Lowering by Pravastatin on Progression of Asymptomatic Carotid Atherosclerosis | 6.0 | 159 | Citations (PDF) |
| 224 | Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension | 2.3 | 91 | Citations (PDF) |
| 225 | Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial | 62.3 | 2,478 | Citations (PDF) |
| 226 | Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial | 62.3 | 552 | Citations (PDF) |
| 227 | The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization | 2.2 | 88 | Citations (PDF) |
| 228 | Design of the Syst-Eur trial and Syst-Eur Phase 2 | 2.2 | 0 | Citations (PDF) |
| 229 | Latin American consensus on diabetes mellitus and hypertension | 2.2 | 18 | Citations (PDF) |
| 230 | High prevalence of retinal vascular changes in never‐treated essential hypertensives: an inter‐ and intra‐observer reproducibility study with non‐mydriatic retinography | 1.7 | 28 | Citations (PDF) |
| 231 | Cardiovascular target organ damage in essential hypertensives with or without reproducible nocturnal fall in blood pressure | 2.2 | 174 | Citations (PDF) |
| 232 | Absolute and relative changes in carotid intima???media thickness and atherosclerotic plaques during long-term antihypertensive treatment | 2.2 | 38 | Citations (PDF) |
| 233 | Metabolic syndrome and target organ damage in untreated essential hypertensives | 2.2 | 172 | Citations (PDF) |
| 234 | Retinal microvascular changes and target organ damage in untreated essential hypertensives | 2.2 | 73 | Citations (PDF) |
| 235 | Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial | 2.2 | 177 | Citations (PDF) |
| 236 | Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertensionThe study on cognition and prognosis in the elderly (SCOPE) | 2.3 | 153 | Citations (PDF) |
| 237 | Translating worldwide calcium-channel blocker experience into clinical practice | 2.0 | 0 | Citations (PDF) |
| 238 | Emerging data on calcium-channel blockers: The COHORT study | 2.0 | 22 | Citations (PDF) |
| 239 | Non-dipper treated hypertensive patients do not have increased cardiac structural alterations | 1.5 | 42 | Citations (PDF) |
| 240 | Relationship between plasma insulin and left ventricular mass in normotensive participants of the Gubbio Study | 2.3 | 12 | Citations (PDF) |
| 241 | The value triallong-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk | 2.0 | 0 | Citations (PDF) |
| 242 | VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk | 2.0 | 103 | Citations (PDF) |
| 243 | Principal Results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial | 16.6 | 657 | Citations (PDF) |
| 244 | New year, new challenges | 2.2 | 14 | Citations (PDF) |
| 245 | The Study on Cognition and Prognosis in the Elderly (SCOPE) | 2.2 | 1,275 | Citations (PDF) |
| 246 | Left ventricular hypertrophy in treated hypertensive patients with good blood pressure control outside the clinic, but poor clinic blood pressure control | 2.2 | 22 | Citations (PDF) |
| 247 | Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles | 2.2 | 112 | Citations (PDF) |
| 248 | Costs of implementing recommendations on hypertension management given in recent guidelines | 2.2 | 9 | Citations (PDF) |
| 249 | Left ventricular hypertrophy regression with antihypertensive treatment: focus on candesartan | 1.7 | 10 | Citations (PDF) |
| 250 | Results of Antihypertensive Treatment Trials in the Elderly | 0.2 | 10 | Citations (PDF) |
| 251 | Cardiac and renal damage in the elderly hypertensive. | 6.1 | 2 | Citations (PDF) |
| 252 | Calcium Antagonist Lacidipine Slows Down Progression of Asymptomatic Carotid Atherosclerosis | 18.1 | 514 | Citations (PDF) |
| 253 | John Chalmers’ Festschrift | 2.2 | 0 | Citations (PDF) |
| 254 | Neuronal nitric oxide synthase and renin stimulation by sodium deprivation are dependent on the renal nerves | 2.2 | 8 | Citations (PDF) |
| 255 | News, Reminiscences and Perspectives: a new section of the Journal of Hypertension | 2.2 | 0 | Citations (PDF) |
| 256 | Assessment of carotid plaque composition in hypertensive patients by ultrasonic tissue characterization: a validation study | 2.2 | 19 | Citations (PDF) |
| 257 | Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy | 2.2 | 109 | Citations (PDF) |
| 258 | Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy. | 2.2 | 71 | Citations (PDF) |
| 259 | Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension | 2.2 | 108 | Citations (PDF) |
| 260 | Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey | 2.2 | 159 | Citations (PDF) |
| 261 | Factors influencing acute ischaemia-induced renal hypertension in rats | 2.2 | 3 | Citations (PDF) |
| 262 | Systolic vs Diastolic Blood Pressure Control in the Hypertensive Patients of the PAMELA Population | 8.1 | 98 | Citations (PDF) |
| 263 | Coping with the challenges of the next four years | 2.2 | 10 | Citations (PDF) |
| 264 | Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk | 2.2 | 65 | Citations (PDF) |
| 265 | Cognitive Function and Health-Related Quality of Life in Elderly Patients with Hypertension - Baseline Data from the Study on COgnition and Prognosis in the Elderly (SCOPE) | 1.7 | 33 | Citations (PDF) |
| 266 | Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives | 2.0 | 113 | Citations (PDF) |
| 267 | Red blood cell count in short-term prediction of cardiovascular disease incidence in the Gubbio population Study | 1.3 | 32 | Citations (PDF) |
| 268 | Characteristics of 15314 Hypertensive Patients at High Coronary Risk. The VALUE Trial | 1.7 | 84 | Citations (PDF) |
| 269 | Serum uric acid for short term prediction of cardiovascular disease incidence in the Gubbio population Study | 1.3 | 47 | Citations (PDF) |
| 270 | Target organ damage and non-dipping pattern defined by two sessions of ambulatory blood pressure monitoring in recently diagnosed essential hypertensive patients | 2.2 | 154 | Citations (PDF) |
| 271 | Risk assessment and treatment benefit in intensively treated hypertensive patients of the Hypertension Optimal Treatment (HOT) study | 2.2 | 57 | Citations (PDF) |
| 272 | Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study | 2.2 | 137 | Citations (PDF) |
| 273 | Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA) | 2.2 | 250 | Citations (PDF) |
| 274 | High prevalence of cardiac and extracardiac target organ damage in refractory hypertension | 2.2 | 251 | Citations (PDF) |
| 275 | Cardiovascular risk stratification in hypertensive patients: Impact of echocardiography and carotid ultrasonography | 2.2 | 28 | Citations (PDF) |
| 276 | Role of the renal nerves in the control of renin synthesis during different sodium intakes in the rat | 2.2 | 12 | Citations (PDF) |
| 277 | Systolic and pulse blood pressures (but not diastolic blood pressure and serum cholesterol) are associated with alterations in carotid intima–media thickness in the moderately hypercholesterolaemic hypertensive patients of the Plaque Hypertension Lipid Lowering Italian Study | 2.2 | 102 | Citations (PDF) |
| 278 | Impact of the Gubbio population study on community control of blood pressure and hypertension | 2.2 | 42 | Citations (PDF) |
| 279 | Transient but not sustained blood pressure increments by occupational noise. An ambulatory blood pressure measurement study | 2.2 | 54 | Citations (PDF) |
| 280 | Efficacy, Tolerability, and Impact on Quality of Life of Long-Term Treatment with Manidipine or Amlodipine in Patients with Essential Hypertension | 2.0 | 54 | Citations (PDF) |
| 281 | The antiatherogenic effects of antihypertensive treatment: Trials completed and ongoing | 4.8 | 13 | Citations (PDF) |
| 282 | Renal Function and Intensive Lowering of Blood Pressure in Hypertensive Participants of the Hypertension Optimal Treatment (HOT) Study | 0.4 | 421 | Citations (PDF) |
| 283 | Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study | 2.2 | 105 | Citations (PDF) |
| 284 | Prevalence of target organ damage in treated hypertensive patients | 2.2 | 30 | Citations (PDF) |
| 285 | Patterns of hypertension management in Italy | 2.2 | 87 | Citations (PDF) |
| 286 | Baseline reproducibility of B-mode ultrasonic measurement of carotid artery intima – media thickness | 2.2 | 134 | Citations (PDF) |
| 287 | Effects of a reversible ‘nephrectomy’ on renal sympathetic activity and blood pressure in the rat | 2.2 | 7 | Citations (PDF) |
| 288 | Guidelines for the use of self-blood pressure monitoring | 2.2 | 202 | Citations (PDF) |
| 289 | Pulse pressure and isolated systolic hypertension: Association with microalbuminuria | 5.3 | 84 | Citations (PDF) |
| 290 | Target Blood Pressure in Elderly Hypertensive Patients: How Low Should You Go? | 1.7 | 1 | Citations (PDF) |
| 291 | Cardiac, renal and vascular complications in the diabetic patient | 6.1 | 0 | Citations (PDF) |
| 292 | Antihypertensive Efficacy of Manidipine and Enalapril in Hypertensive Diabetic Patients | 2.0 | 21 | Citations (PDF) |
| 293 | Effects of Adenosine Receptor Agonists on Efferent Renal Nerve Activity in Anesthetized Rats | 2.0 | 1 | Citations (PDF) |
| 294 | Evidence-based medicine | 2.2 | 4 | Citations (PDF) |
| 295 | Blood pressure control in a hypertension hospital clinic | 2.2 | 27 | Citations (PDF) |
| 296 | Impact of nocturnal fall in blood pressure on early cardiovascular changes in essential hypertension | 2.2 | 36 | Citations (PDF) |
| 297 | Cardiovascular Disease and the Kidney: An Epidemiologic Overview | 2.0 | 23 | Citations (PDF) |
| 298 | Rationale and Design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial | 2.8 | 91 | Citations (PDF) |
| 299 | Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial | 62.3 | 5,529 | Citations (PDF) |
| 300 | Postischemic Left Ventricular Dysfunction Is Abolished by Alpha-Adrenergic Blocking Agents 11This study was supported by institutional funds from the University of Milan (MURST 60%). Hewlett Packard Germany provided the echocardiographic equipment used in this study; Hewlett Packard Italiana S.P.A. provided technologic assistance in the acquisition of the data presented here. | 2.3 | 52 | Citations (PDF) |
| 301 | Clinical Advantages of Lipophilic Dihydropyridines | 1.7 | 9 | Citations (PDF) |
| 302 | Subgroup and Per-Protocol Analysis of the Randomized European Trial on Isolated Systolic Hypertension in the Elderly | 8.1 | 124 | Citations (PDF) |
| 303 | Clinical Advantages of Lipophilic Dihydropyridines | 1.7 | 3 | Citations (PDF) |
| 304 | Updating recommendations for prevention of coronary heart disease | 2.2 | 0 | Citations (PDF) |
| 305 | Searching for information from unreported trials – amnesty for the past and prospective meta-analyses for the future | 2.2 | 3 | Citations (PDF) |
| 306 | Risk factors associated with alterations in carotid intima—media thickness in hypertension | 2.2 | 266 | Citations (PDF) |
| 307 | Prevalence of episodes of ST-segment depression among mild-to-moderate hypertensive patients in northern Italy | 2.2 | 27 | Citations (PDF) |
| 308 | Seasonal variations in home and ambulatory blood pressure in the PAMELA population | 2.2 | 188 | Citations (PDF) |
| 309 | Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements | 2.2 | 43 | Citations (PDF) |
| 310 | Looking back on three years of Editorship | 2.2 | 13 | Citations (PDF) |
| 311 | The Verapamil in Hypertension and Atherosclerosis Study (VHAS) | 2.2 | 218 | Citations (PDF) |
| 312 | 24-Hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring | 2.2 | 58 | Citations (PDF) |
| 313 | Effects of antihypertensive treatment on vasopressin secretion and on its osmoregulation in moderate hypertension | 2.2 | 3 | Citations (PDF) |
| 314 | The Hypertensive Patient With Multiple Risk Factors Is Treatment Really So Difficult? | 2.0 | 21 | Citations (PDF) |
| 315 | Blood-pressure control in the hypertensive population | 62.3 | 283 | Citations (PDF) |
| 316 | Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension | 62.3 | 2,909 | Citations (PDF) |
| 317 | Electrophysiological evidence of ipsilateral reno–renal reflexes in the cat | 2.5 | 3 | Citations (PDF) |
| 318 | Ambulatory Blood Pressure Is Superior to Clinic Blood Pressure in Predicting Treatment-Induced Regression of Left Ventricular Hypertrophy | 18.1 | 511 | Citations (PDF) |
| 319 | Ambulatory and Home Blood Pressure Normality in the Elderly | 6.6 | 136 | Citations (PDF) |
| 320 | Safety Aspects of Treatment with Lacidipine—A Slow-onset, Long-acting Calcium Antagonist | 1.7 | 12 | Citations (PDF) |
| 321 | Trials investigating the anti-atherosclerotic effects of antihypertensive drugs | 2.2 | 12 | Citations (PDF) |
| 322 | Safety of the calcium antagonist lacidipine evaluated from a phase III???IV trial database | 2.2 | 3 | Citations (PDF) |
| 323 | Ambulatory blood pressure monitoring | 2.2 | 22 | Citations (PDF) |
| 324 | Left ventricular concentric remodelling and carotid structural changes in essential hypertension | 2.2 | 57 | Citations (PDF) |
| 325 | Editors?? Corner: Benefits and cost-effectiveness of antihypertensive therapy. The actuarial versus the intervention trial approach | 2.2 | 26 | Citations (PDF) |
| 326 | Current position of calcium antagonists in hypertension | 2.2 | 12 | Citations (PDF) |
| 327 | Similarities and differences in structural and functional changes of left ventricle and carotid arteries in young borderline hypertensives and in athletes | 2.2 | 32 | Citations (PDF) |
| 328 | Editors?? corner: debating the value of absolute versus relative risk | 2.2 | 6 | Citations (PDF) |
| 329 | White-coat hypertension: misnomers, misconceptions and misunderstandings. What should we do next? | 2.2 | 120 | Citations (PDF) |
| 330 | Excretory Responses to Renal Nerve Stimulation During Inhibition of Neutral Metalloendopeptidase and Angiotensin-Converting Enzyme in the Rat | 2.0 | 2 | Citations (PDF) |
| 331 | Calculation of trough: peak ratio of antihypertensive treatment from ambulatory blood pressure: methodological aspects | 2.2 | 93 | Citations (PDF) |
| 332 | Evaluating the benefits of an antihypertensive agent using trials based on event and organ damage: the Systolic Hypertension in the Elderly Long-term Lacidipine (SHELL) trial and the European Lacidipine Study on Atherosclerosis (ELSA) | 2.2 | 20 | Citations (PDF) |
| 333 | Antihypertensive therapy | 2.2 | 6 | Citations (PDF) |
| 334 | Ambulatory blood pressure normality | 2.2 | 445 | Citations (PDF) |
| 335 | Cardiac and carotid structure in patients with established hypertension and white-coat hypertension | 2.2 | 49 | Citations (PDF) |
| 336 | Guidelines for the management of hypertension: the world Health organisation/International society of Hypertension View | 2.2 | 18 | Citations (PDF) |
| 337 | New European studies on atherosclerosis in hypertension | 0.0 | 0 | Citations (PDF) |
| 338 | Vascular complications in hypertension: The VHAS study | 2.1 | 2 | Citations (PDF) |
| 339 | Woven left coronary artery disease | 1.8 | 19 | Citations (PDF) |
| 340 | Ambulatory Blood Pressure Monitoring in the Evaluation of Antihypertensive Treatment: Additional Information from a Large Data Base | 1.7 | 92 | Citations (PDF) |
| 341 | Overview | 2.2 | 0 | Citations (PDF) |
| 342 | Lack of placebo effect on ambulatory blood pressure | 2.0 | 122 | Citations (PDF) |
| 343 | VIEWPOINT The Antiatherosclerotic Effect of Calcium Antagonists in Man—What did MIDAS Actually Show? | 1.7 | 15 | Citations (PDF) |
| 344 | Hemodynamic and Humoral Effects of Chronic Treatment with the Neutral Endopeptidase Inhibitor SCH 42495 in Spontaneously Hypertensive Rats | 2.0 | 9 | Citations (PDF) |
| 345 | Goals of Antihypertensive Treatment and Planning of Therapeutic Trials | 2.0 | 10 | Citations (PDF) |
| 346 | Treatment Perspectives in Hypertension | 2.0 | 33 | Citations (PDF) |
| 347 | Impairment of the arterial baroreflex during symptomatic and silent myocardial ischemia in humans | 2.3 | 26 | Citations (PDF) |
| 348 | The 1993 Guidelines for the Management of Mild Hypertension: Memorandum from a WHO/ISH Meeting | 1.7 | 109 | Citations (PDF) |
| 349 | Evaluation of organ damage in hypertension | 2.2 | 12 | Citations (PDF) |
| 350 | Short- and Long-Term Perspectives of Antihypertensive Therapy An Introduction | 2.0 | 8 | Citations (PDF) |
| 351 | The Antiatherogenic Effects of Antihypertensive Drugs: Experimental and Clinical Evidence | 0.3 | 21 | Citations (PDF) |
| 352 | Goals of Antihypertensive Treatment: Prevention of Cardiovascular Events and Prevention of Organ Damage | 1.7 | 40 | Citations (PDF) |
| 353 | Evaluation of the antihypertensive effect of once-a-day trandolapril by 24-hour ambulatory blood pressure monitoring | 1.8 | 27 | Citations (PDF) |
| 354 | Cardiopulmonary receptor and arterial baroreceptor reflexes after acute myocardial infarction | 1.8 | 20 | Citations (PDF) |
| 355 | Has Antihypertensive Treatment Prevented Vascular Disease or Vascular Events? | 2.0 | 8 | Citations (PDF) |
| 356 | Regulation of vasopressin release in moderately severe essential hypertension | 1.9 | 6 | Citations (PDF) |
| 357 | Antihypertensive Treatment | 2.0 | 3 | Citations (PDF) |
| 358 | Multiple risk factors in hypertension: results from the Gubbio Study | 2.2 | 65 | Citations (PDF) |
| 359 | Concluding remarks | 2.2 | 0 | Citations (PDF) |
| 360 | Interactions between the sympathetic nervous system and atrial natriuretic factor in the control of renal functions | 2.2 | 8 | Citations (PDF) |
| 361 | Effects of dilevalol on forearm circulation in essential hypertension | 1.8 | 3 | Citations (PDF) |
| 362 | Investigation of reflexes from volume and baroreceptors during converting-enzyme inhibition in humans | 2.9 | 20 | Citations (PDF) |
| 363 | Value of Echocardiographic and Ambulatory Blood Pressure Monitoring in Hypertension | 0.3 | 4 | Citations (PDF) |
| 364 | Right ventricular wall thickness and function in hypertensive patients with and without left ventricular hypertrophy: echo-Doppler study | 2.2 | 14 | Citations (PDF) |
| 365 | How much should blood pressure be lowered? The problem of the J-shaped curve | 2.2 | 17 | Citations (PDF) |
| 366 | Effect on resting blood pressure and blood pressure homeostasis of short-term administration of the alpha1-adrenergic receptor antagonist, trimazosin, in hypertension | 2.1 | 1 | Citations (PDF) |
| 367 | Evaluation of the antihypertensive effect of celiprolol by ambulatory blood pressure monitoring | 1.8 | 17 | Citations (PDF) |
| 368 | The renin-angiotensin system and the heart | 2.0 | 4 | Citations (PDF) |
| 369 | Baroreflex Sensitivity and Its Evolution During the First Year After Myocardial Infarction | 2.3 | 156 | Citations (PDF) |
| 370 | Calcium Antagonists and Neural Control of Circulation in Essential Hypertension | 2.2 | 10 | Citations (PDF) |
| 371 | Calcium Antagonists and Responsiveness of the Adrenal Glands to Aldosterone-Releasing Stimuli in Hypertensive Patients | 2.2 | 5 | Citations (PDF) |
| 372 | Afferent Pathways of Neural Reno-Renal Reflexes Controlling Sodium and Water Excretion in the Cat | 2.2 | 17 | Citations (PDF) |
| 373 | Discussion on the Natriuretic Effect of Calcium Antagonists | 2.0 | 7 | Citations (PDF) |
| 374 | Role of calcium antagonists in systemic hypertension | 1.8 | 42 | Citations (PDF) |
| 375 | Effects of Reversible Renal Denervation on Haemodynamic and Excretory Functions of the Ipsilateral and Contralateral Kidney in the Cat | 2.2 | 11 | Citations (PDF) |
| 376 | Effects of Celiprolol on Reflex Control of the Cardiovascular System in Essential Hypertension | 2.0 | 35 | Citations (PDF) |
| 377 | Participation of the Renin-angiotensin System in the Maintenance of Blood Pressure During Changes in Posture in Patients with Essential Hypertension | 2.2 | 13 | Citations (PDF) |
| 378 | A Re-examination of Stepped-Care | 2.0 | 18 | Citations (PDF) |
| 379 | A Non-Invasive Index of Leg Arterial Perfusion Pressure During Walking, Derived From Cutaneous Toe Temperature | 1.9 | 1 | Citations (PDF) |
| 380 | Hemodynamic Factors Changing Blood Flow Velocity Waveform and Profile in Normal Human Brachial Artery | 1.9 | 22 | Citations (PDF) |
| 381 | Treatment goals in hypertension | 2.0 | 10 | Citations (PDF) |
| 382 | Summary of prazosin lipid studies | 2.0 | 53 | Citations (PDF) |
| 383 | Twenty-four-hour blood pressure profile and blood pressure variability in untreated hypertension and during antihypertensive treatment by once-a-day nadolol | 2.9 | 18 | Citations (PDF) |
| 384 | Arterial baroreceptor control of blood pressure in man | 2.5 | 31 | Citations (PDF) |
| 385 | Comparison of Cardiovascular, Renal, and Humoral Effects of Acute Administration of Two Calcium Channel Blockers in Normotensive and Hypertensive Subjects | 2.0 | 154 | Citations (PDF) |
| 386 | Modification of arterial baroreflexes by captopril in essential hypertension | 1.8 | 83 | Citations (PDF) |
| 387 | Acute hypotensive and renin-stimulating actions of captopril before and during treatment with a beta-blocking drug | 1.8 | 3 | Citations (PDF) |
| 388 | Alterations of Cardiovascular Reflexes in Hypertension | 1.1 | 3 | Citations (PDF) |
| 389 | Neural mechanisms in life-threatening arrhythmias | 2.9 | 183 | Citations (PDF) |
| 390 | Methyldopa and neural control of circulation in essential hypertension | 1.8 | 23 | Citations (PDF) |
| 391 | Control of blood pressure by carotid sinus baroreceptors in human beings | 1.8 | 89 | Citations (PDF) |
| 392 | Overview of cardiovascular reflexes in hypertension | 1.8 | 32 | Citations (PDF) |
| 393 | Relation between the hypotensive and renin-suppressing activities of alpha methyldopa in hypertensive patients | 1.8 | 6 | Citations (PDF) |
| 394 | Control of renin release: A review of experimental evidence and clinical implications | 1.8 | 76 | Citations (PDF) |
| 395 | Mechanisms of Renal Release of Renin by Electrical Stimulation of the Brainstem in the Cat | 13.2 | 89 | Citations (PDF) |
| 396 | Central and Reflex Regulation of Sympathetic Vasoconstrictor Activity to Limb Muscles during Desynchronized Sleep in the Cat | 13.2 | 35 | Citations (PDF) |
| 397 | Relation of cardiovascular changes in fighting to emotion and exercise* | 3.4 | 84 | Citations (PDF) |
| 398 | Specific Appearance of Sympathetic Cholinergic Vasodilatation in Muscles during Conditioned Movements | 37.9 | 114 | Citations (PDF) |
| 399 | Hemodynamic Patterns during Desynchronized Sleep in Intact Cats and in Cats with Sinoaortic Deafferentation | 13.2 | 41 | Citations (PDF) |
| 400 | Neural and Non-neural Mechanisms influencing Circulation during Sleep | 37.9 | 57 | Citations (PDF) |
| 401 | Cardiovascular Changes during Preparation for Fighting Behaviour in the Cat | 37.9 | 40 | Citations (PDF) |
| 402 | Regulation of circulation by carotid sinus, aortic and cardiopulmonary receptors | 3.4 | 0 | Citations (PDF) |
| 403 | AUTONOMIC HYPOTHALAMIC OUTBURSTS ELICITED BY CEREBELLAR STIMULATION | 2.1 | 142 | Citations (PDF) |
